Strategic partnerships Nanoscope’s collaboration with industry players like Catalent for commercialization and McKesson InspiroGene for U.S. distribution signals a readiness to integrate with large biopharma ecosystems, creating potential co-marketing, distribution, and manufacturing collaboration opportunities.

Regulatory momentum With FDA Fast Track and Orphan Drug designations for RP and SD, plus EMA Orphan Drug designation, there is a favorable regulatory pathway that can shorten time-to-market, enabling sales teams to target early adopters and specialty clinics more aggressively.

Clinical pipeline A disease-agnostic optogenetic platform (MCO-010) across RP, SD, GA, LCA and other retinal conditions offers multiple entry points for ophthalmology practices, clinics, and payer discussions, expanding potential addressable market beyond a single indication.

Commercial readiness Lead product MOGENRY delivery via in-office, one-time injection aligns with existing ophthalmology workflows, reducing patient burden and payer barriers, and enabling straightforward adoption by clinics and hospital networks.

Market positioning Positioning as a disease-agnostic vision-restoration platform differentiates Nanoscope from disease-specific gene therapies, presenting a broad value proposition to health systems, payers, and patient advocacy groups seeking scalable retinal solutions.